Table V.
Scoring of detected congestion, inflammation, oedema and necrosis in lung tissues of mice groups infected with MRSA clinical isolate S19 and treated with zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin at a dose of 20 mg/kg of body weight/day.
| Histological observationa | (Score 0–3) | |||
|---|---|---|---|---|
| ZABb | MOX | LEV | CIP | |
| Congestion | 0 (40%) | |||
| +1 (20%) | +1 (60%) | +2 (80%) | +3 (60%) | |
| +2 (40%) | +2 (40%) | +1 (20%) | +1 (40%) | |
| Inflammation | 0 (40%) | |||
| +1 (20%) | +1 (60%) | +2 (80%) | +3 (60%) | |
| +2 (40%) | +2 (40%) | +1 (20%) | +1 (40%) | |
| Edema | 0 (40%) | |||
| +1 (20%) | +1 (60%) | +2 (80%) | +3 (60%) | |
| +2 (40%) | +2 (40%) | +1 (20%) | +1 (40%) | |
| Necrosis | 0 (40%) | |||
| +1 (20%) | +1 (60%) | +2 (80%) | +3 (60%) | |
| +2 (40%) | +2 (40%) | +1 (20%) | +1 (40%) | |
a
Randomly selected sections blindly scored with a score applied to review of a whole lung section, scored at X10 magnification.
b
ZAB: Zabofloxacin, MOX: moxifloxacin, LEV: levofloxacin and CIP: ciprofloxacin.